3 Top Challenges Facing Regulatory Professionals Right Now

Why It Matters

These issues directly affect drug development timelines, compliance costs, and the ability to bring innovative therapies to market, making regulatory agility a competitive advantage.

Key Takeaways

• FDA AI guidance lacks depth, only ten principles
• Early FDA dialogue prevents rejection of AI‑enhanced submissions
• Freeze AI models for regulatory review, treat outputs as supportive
• Radiopharma faces limited isotope suppliers and FDA inspection constraints
• Proactive regulator engagement improves clarity and approval speed

Pulse Analysis

The FDA and EMA’s recent two‑page AI guidance marks a symbolic step toward modernizing drug development, yet its brevity leaves companies searching for concrete implementation pathways. Regulators outlined ten high‑level principles without detailed expectations, prompting consultants like Gurpreet Gill‑Sangha to warn that robust, fundamentals‑first applications remain the cornerstone of approval. By initiating pre‑submission conversations, firms can clarify how AI augments rather than replaces traditional evidence, reducing the risk of complete response letters.

A deeper tension emerges from the inherent dynamism of AI‑driven discovery platforms. As Rahul Gupta notes, regulatory frameworks were built for static products, while AI models continuously learn and evolve. This creates uncertainty about whether a model that has been updated remains a validated tool. The pragmatic solution—freezing models for the regulatory review period, transparently disclosing data limitations, and positioning AI outputs as supportive evidence—allows innovators to maintain momentum without forcing regulators to overhaul their evaluation timelines. Early alignment meetings further cement expectations before precedents solidify.

Supply‑chain constraints add another layer of complexity, especially in the niche radiopharmaceutical sector. Limited isotope sources and the FDA’s requirement for commercial‑stage products before site inspections make securing manufacturing capacity a strategic hurdle. Ayda Delpassand advises locking in qualified suppliers early and partnering with CDMOs that already hold FDA authorizations. Viewing the FDA as an ally rather than an obstacle, and maintaining proactive, clear communication, not only smooths the approval pathway but also accelerates patient access to cutting‑edge therapies.